Mary Cunningham, MD

EAY191-N5: A RANDOMIZED TRIAL OF NERATINIB, A PAN-ERBB INHIBITOR, ALONE OR IN COMBINATION WITH PALBOCICLIB, A CDK4/6 INHIBITOR, IN PATIENTS WITH HER2+ GYNECOLOGIC CANCERS AND OTHER SOLID TUMORS A ComboMATCH Treatment Trial
Read more

EAY191-N4: A RANDOMIZED TRIAL OF SELUMETINIB AND OLAPARIB OR SELUMETINIB ALONE IN PATIENTS WITH RECURRENT OR PERSISTENT RAS PATHWAY MUTANT OVARIAN AND ENDOMETRIAL. (ComboMATCH)
Read more

EAY191-Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Read more

NRG-GY026, A Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) or pertuzumab trastuzumab and hyaluronidase-zzfx (PHESGO) in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma. (#NCT05256225)
Read more

NRG-CC008: A NON-RANDOMIZED PROSPECTIVE CLINICAL TRIAL COMPARING THE NON-INFERIORITY OF SALPINGECTOMY TO SALPINGO-OOPHORECTOMY TO REDUCE THE RISK OF OVARIAN CANCER AMONG BRCA1 CARRIERS [SOROCk]
Read more

NRG-GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Read more

A Phase II Study of Abemaciclib in Combination with Letrozole in Advanced, Recurrent or Metastatic Endometrioid Endometrial Cancer
Read more